Market Overview

Goldman Sachs Downgrades Aetna To Neutral

Share:
Related AET
Argus Talks Humana-Aetna Deal Uncertainty, Raises EPS Estimates For Humana
Aetna's Withdrawal From Obamacare Linked To DOJ's Issues With Humana Acquisition
Tracking Larry Robbins' Glenview Capital Management Portfolio - Q2 2016 Update (Seeking Alpha)

Analysts at Goldman Sachs downgraded Aetna (NYSE: AET) from Buy to Neutral.

The target price for Aetna has been lowered from $94.00 to $88.00.

Aetna shares have surged 24.00% over the past 52 weeks, while the S&P 500 index has gained 13.56% in the same period.

Aetna's shares dropped 0.61% to $77.84 in pre-market trading.

Latest Ratings for AET

DateFirmActionFromTo
Jul 2016Wolfe ResearchDowngradesOutperformPeer Perform
Jun 2016BernsteinInitiates Coverage onOutperform
Apr 2016ClevelandInitiates Coverage onNeutral

View More Analyst Ratings for AET
View the Latest Analyst Ratings

Posted-In: Goldman SachsDowngrades Analyst Ratings

 

Related Articles (AET)

View Comments and Join the Discussion!